Scienture Holdings raises $3.9 million in registered direct offering

NEW YORK - Scienture Holdings, Inc. (NASDAQ:SCNX) announced Thursday it has entered into a securities purchase agreement with institutional investors to sell 3,225,000 shares of common stock at $1.20 per share in a registered direct offering. The offering price represents a significant discount to the current trading price of $2.22, with the company’s market capitalization standing at approximately $36 million.

The pharmaceutical holding company expects to generate approximately $3.9 million in gross proceeds before deducting placement agent fees and other offering expenses. The offering is expected to close on August 15, 2025, subject to customary closing conditions. According to InvestingPro data, this capital raise comes as the company faces liquidity challenges, with a concerning current ratio of 0.11 and short-term obligations exceeding liquid assets.

Maxim Group LLC is serving as the sole placement agent for the transaction, which is being conducted under an effective shelf registration statement previously filed with the SEC on August 1, 2025, and declared effective on August 8, 2025.

Scienture Holdings describes itself as a company focused on developing and distributing novel specialty pharmaceutical products. Through its wholly owned subsidiary, Scienture, LLC, the company aims to provide products across various therapeutic areas.

The company stated that a prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website.

The announcement was made in a press release issued by the company.

In other recent news, Scienture Holdings, Inc. announced it has secured approximately $1.2 million in bridge funding by issuing common stock to institutional or accredited investors. The company’s board of directors has approved a total bridge funding raise of up to $3 million, with no warrants, options, or other convertible securities included that could dilute existing stockholders. Additionally, Scienture Holdings has regained compliance with Nasdaq’s minimum bid price requirement, as its stock traded above $1.00 per share for ten consecutive business days. This follows a notification received from Nasdaq on May 19, 2025, regarding non-compliance with the exchange’s listing rule. Furthermore, Scienture Holdings has terminated its Equity Line of Credit (ELOC) facility, effective May 22, 2025. The company filed a post-effective amendment to deregister 310,488 unsold shares of common stock previously registered under the facility. These developments come as the company prepares for an upcoming product launch.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.